Last reviewed · How we verify
NCT04718233
Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss
Phase 2 trial testing Sildenafil 25Mg Tablet in Recurrent Pregnancy Loss in 80 participants. Completed in 1 July 2019.
1 July 2019
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 5 September 2018 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 July 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Sildenafil 25Mg Tablet — full drug profile →
- Placebo Oral Tablet — full drug profile →
Conditions studied
- Recurrent Pregnancy Loss — all drugs for Recurrent Pregnancy Loss →
Sponsor
Ain Shams University
Who can join
Adults 18 to 35, female only, with Recurrent Pregnancy Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with recurrent pregnancy loss are known to have decreased uterine artery blood flow. Nitric oxide plays a major role in increasing uterine blood flow during the luteal phase. This study is done to evaluate the effects of sildenafil on blood flow indices in the patients with recurrent pregnancy loss due to impaired uterine artery blood flow.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04718233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Pregnancy Loss
Currently open trials in the same condition.
- NCT06968026 — Effects of High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomi · NA · recruiting
- NCT05725512 — Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages · Phase 4 · recruiting
- NCT06182878 — Tender Loving Care for Recurrent Pregnancy Loss · NA · recruiting
- NCT05989178 — Prospective Recurrent Pregnancy Loss Registry · recruiting
- NCT06007560 — Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss · NA · active not recruiting
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04718233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 22 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04718233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing